Published: 22 August 2019
Author(s): Baojian Liu, Ming Bai, Yan Wang, Di Wang, Jin Zhao, Lu Li, Ruijuan Dong, Shiren Sun
Issue: August 2019
Section: Original Article

The role of bortezomib in the treatment of immunoglobulin light chain (AL) amyloidosis is not well defined. We performed this meta-analysis to evaluate the efficacy and safety of bortezomib-based regimens in patients with AL amyloidosis who are not eligible for or refuse autologous stem cell transplantation.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.